Andrew "Andy" Sheldon
Mr. Sheldon has thirty years of experience in the pharmaceutical industry, and was named CEO of the Year by the Vaccine Industry Excellence awards at the World Vaccine Congress in April 2012. Before joining Medicago, Mr. Sheldon served as Vice President, Sales and Marketing, of Shire Biologics. He was responsible for international expansion with European, American and Asian private partnership agreements. During his tenure at Shire, his notable accomplishments included negotiating the annual and pandemic influenza vaccine contract with the federal and provincial governments, and managing the approval of a bladder cancer therapeutic vaccine by the U.S. Food and Drug Administration (FDA).
Mr. Sheldon has a bachelor’s degree in agricultural sciences from Université Laval, Québec City, and a bachelor’s of science degree with honors in biological sciences from the University of East Anglia, in Norwich, England.
Mr. Dawe is an accomplished entrepreneur, financier and investor based in Halifax, Nova Scotia Canada. He currently serves as Chairman of Pivot Technology Solutions Inc., a TSX listed company and CEO of Fortune Bay Corp., a TSX listed company formed in 2014. Mr. Dawe has founded or co-founded a number of successful companies. He was recently Chairman & Chief Executive Officer of Brigus Gold Corp., a NYSE and TSX publically listed gold production company. Brigus Gold was acquired by Primero Mining Corp. in March, 2014. Mr. Dawe holds a Bachelor of Commerce degree from Memorial University of Newfoundland (MUN), where he currently serves on the Advisory board to the Faculty of Business Administration. Mr. Dawe, a native of Newfoundland and Labrador, also serves on the Queen Elizabeth ll Hospital Foundation and is a member of the Young Presidents’ Organization (YPO), an international organization for business leaders. He established and personally funds the annual James R. Pearcey Entrepreneurial Scholarship at MUN and recently funded DC Makes, a new entrepreneurship-based program at the Discovery Centre in Halifax, NS.
Mr. Hall is Vice President of Callidus Capital Corporation – a specialized asset-based lender to companies in Canada and the United States. He is also President of James Hall Advisors Inc., a financial and management advisory firm. Prior to Advisors, Mr. Hall was Chairman and Chief Executive Officer of Philadelphia-based pure-play newspaper company Journal Register Company, and served as Senior Vice President & Chief Investment Officer of private equity investment fund Working Ventures Canadian Fund Inc. from 1990 to 2002. Mr. Hall is a director of Atomic Energy of Canada Limited and Trustee of an OMERS Trust. A Chartered Accountant (CPA, CA), Mr. Hall is a graduate of the Richard Ivey School of Business at Western University in London, Ontario.
Chief Executive Officer & Director
Mr. Scardino is a technology and media investor. He has extensive experience as a director of both for-profit and not-for-profit organizations, public and private, in the US and the UK. He was a correspondent, commentator and editor for The New York Times, The Guardian, The Independent, the BBC and Sky News. He has served as a communications director in political campaigns and government. He earned his bachelor’s degree at Columbia University and his master’s at the University of California, Berkeley. He has been an investor in Immunovaccine since 2005, a director since 2010 and was Chairman of the Board from 2011 - 2016.
Alfred "Fred" Smithers
Mr. Smithers is the President and Chief Executive Officer of Iona Resources Holdings Limited. He was founder and former President and Chief Executive Officer of the Secunda Group of Companies. For six consecutive years, Secunda Marine Limited was named one of the “50 Best Managed Companies in Canada” by Deloitte & Touche. Mr. Smithers sold Secunda Marine Services to J. Ray McDermott, an NYSE-listed company, in 2007. In 2003 Mr. Smithers was named one of the “Top 50 CEOs of Atlantic Canada”, and is a member of the Nova Scotia Business Hall of Fame. He received an Honorary Diploma from the Nova Scotia Community College and holds an Honorary Doctorate in Commerce from Saint Mary’s University. With a history of past board appointments, Mr. Smithers currently sits on the Board of Directors of the Dartmouth General Hospital, and is on the Advisory Board of Atlantic Signature Mortgage & Loan. He is a recipient of the Canadian Red Cross Humanitarian Award, an Officer of the Order of Canada, and the Honorary British Consul for the Maritimes.
Shermaine Tilley is a Managing Partner at CTI Life Sciences Fund, a Montreal-based venture capital fund investing across Canada as well as in the U.S..CTI LSF currently has $245 M under management, comprised of 2014 vintage Fund II that is open for investment as well as a 2006 vintage Fund I. Since joining CTI LSF at its inception in 2006, Shermaine has played a critical role in each of the investments made by the Fund, but particularly by leading investments in Medicago – acquired by Mitsubishi Tanabe for $357 M in 2013 – as well as those in Phemi, Xagenic and Zymeworks. She was also a board observer in Enobia that was acquired by Alexion in 2012 in the largest takeout of a private development-stage biotech for $1.1B, assuming all milestones are received. Prior to joining CTI LSF in 2006, Dr. Tilley was Senior VP at Drug Royalty Corporation, the world’s first private equity firm doing royalty transactions in the biotech/pharma space. At DRC (now DRI), Dr. Tilley played a leading role in closing 12 transactions totaling over $200 M in investments.